Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $27.71 Consensus Price Target from Brokerages

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have received a consensus recommendation of “Hold” from the twenty-eight ratings firms that are presently covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a sell recommendation, thirteen have given a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $27.7083.

Several analysts have commented on SRPT shares. Needham & Company LLC restated an “underperform” rating on shares of Sarepta Therapeutics in a report on Thursday, March 26th. Mizuho boosted their target price on Sarepta Therapeutics from $26.00 to $31.00 and gave the stock an “outperform” rating in a report on Thursday, March 12th. Weiss Ratings upgraded Sarepta Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, May 8th. Citigroup boosted their target price on Sarepta Therapeutics from $9.00 to $13.00 and gave the stock a “sell” rating in a report on Thursday, March 26th. Finally, Wedbush boosted their target price on Sarepta Therapeutics from $29.00 to $35.00 and gave the stock an “outperform” rating in a report on Thursday, March 26th.

Sarepta Therapeutics Stock Down 3.1%

SRPT opened at $17.01 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.63 and a quick ratio of 2.62. The stock has a market capitalization of $1.80 billion, a price-to-earnings ratio of -17.72, a price-to-earnings-growth ratio of 0.20 and a beta of 0.26. The business has a 50-day moving average of $20.03 and a two-hundred day moving average of $20.09. Sarepta Therapeutics has a 12 month low of $10.41 and a 12 month high of $44.14.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 EPS for the quarter, beating the consensus estimate of $0.98 by $2.18. The company had revenue of $730.80 million during the quarter, compared to analysts’ expectations of $474.16 million. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The firm’s revenue was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($3.42) EPS. On average, research analysts expect that Sarepta Therapeutics will post 3.69 earnings per share for the current year.

Insider Activity

In other news, Director Stephen Mayo sold 7,239 shares of the business’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $17.02, for a total transaction of $123,207.78. Following the completion of the sale, the director owned 1,765 shares in the company, valued at approximately $30,040.30. The trade was a 80.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 6.90% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

A number of institutional investors have recently modified their holdings of the company. Aberdeen Group plc boosted its holdings in Sarepta Therapeutics by 59.6% in the 3rd quarter. Aberdeen Group plc now owns 1,982,764 shares of the biotechnology company’s stock worth $38,208,000 after acquiring an additional 740,360 shares during the period. Mirador Capital Partners LP purchased a new position in Sarepta Therapeutics in the 4th quarter worth approximately $3,012,000. Boxer Capital Management LLC boosted its holdings in Sarepta Therapeutics by 900.0% in the 3rd quarter. Boxer Capital Management LLC now owns 250,000 shares of the biotechnology company’s stock worth $4,818,000 after acquiring an additional 225,000 shares during the period. Wealth Enhancement Advisory Services LLC boosted its holdings in Sarepta Therapeutics by 143.9% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 106,759 shares of the biotechnology company’s stock worth $2,410,000 after acquiring an additional 62,981 shares during the period. Finally, Principal Financial Group Inc. boosted its holdings in Sarepta Therapeutics by 109.1% in the 3rd quarter. Principal Financial Group Inc. now owns 468,067 shares of the biotechnology company’s stock worth $9,020,000 after acquiring an additional 244,181 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.